TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06951217: An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Sponsor: Avalyn Pharma Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 340 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT06951217 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06951217 Rescue Dossier →